LeMaitre Vascular (NASDAQ:LMAT) Posts Earnings Results, Beats Estimates By $0.05 EPS

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) released its earnings results on Thursday. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.44 by $0.05, Briefing.com reports. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The business had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. During the same period last year, the business earned $0.33 earnings per share. The firm's revenue for the quarter was up 15.6% compared to the same quarter last year.

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT traded up $6.49 during midday trading on Friday, reaching $94.88. The company's stock had a trading volume of 343,615 shares, compared to its average volume of 123,348. The business's fifty day simple moving average is $89.53 and its 200-day simple moving average is $82.77. The company has a market capitalization of $2.13 billion, a P/E ratio of 59.86, a P/E/G ratio of 2.33 and a beta of 0.88. LeMaitre Vascular has a fifty-two week low of $45.96 and a fifty-two week high of $101.67.

Wall Street Analyst Weigh In

A number of brokerages recently commented on LMAT. Lake Street Capital began coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They issued a "buy" rating and a $105.00 target price for the company. JMP Securities lifted their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 20th. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price target for the company. StockNews.com lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Tuesday, August 27th. Finally, Barrington Research boosted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research note on Friday. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $94.57.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now directly owns 14,114 shares of the company's stock, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.79% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.